House OKs $4.6B to Counter Bioterrorism
The House, trying "to think as evilly as we could," overwhelmingly passed a $4.6 billion bill today aimed at strengthening the nation's bioterrorism preparedness by stockpiling vaccines and boosting inspections of food coming across borders.
The 425-1 vote capped a months-long effort sparked by post-Sept. 11 concerns that included anthrax-tainted letters sent to Capitol Hill, reports Associated Press Writer Janelle Carter.
"We've tried to think as evilly as we could," said Rep. Billy Tauzin, R-La., a drafter of the bill. "What would the most evil person do to disrupt our health supply system or our clean water system? What would the most evil mind try to do if they learned how to fly a crop-duster? We went through that awful exercise of trying to think like the most evil person on earth."
The bill, which authorizes the money over two years, gives the nation "a whole new arsenal," Tauzin told Carter.
Senate leaders hope to take up the bill before adjourning Friday for a weeklong recess, but it was uncertain whether they would get to it.
States would get $1.6 billion in grants to prepare for a biological attack, using a formula included in the compromise. The House had wanted grant disbursement to be at the discretion of the health and human services secretary.
The compromise also would have drinking water systems assess their vulnerability to terrorist attack, develop emergency plans and submit the plans to the Environmental Protection Agency. House Republicans had argued that the agency lacks the capacity to handle such sensitive information, but the compromise would establish strict security controls to protect the information.
The bill also includes $300 million for the Centers for Disease Control and Prevention to upgrade its facilities.
The compromise also would renew a law that allows the Food and Drug Administration to charge fees to pharmaceutical companies to pay for speedier review of new medications. Negotiators also included $45 million to help speed the review of generic drugs and $27 million to help the FDA monitor pharmaceutical advertising aimed at consumers. Both amounts would be spent over five years.
The only vote against the bill was cast by Rep. Ron Paul, R-Texas.